Fondaparinux versus enoxaparin for acute coronary syndrome a review of the comparative clinical effectiveness and cost-effectiveness
Fondaparinux may offer both advantages and disadvantages when compared to older anticoagulants, such as enoxaparin. It is therefore important, in clinical practice, to assess the risk-benefit profile when determining which anticoagulant agent should be prescribed to patients. This should include con...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Ottawa, Ontario]
Canadian Agency for Drugs and Technologies in Health
3 September 2015, 2015
|
| Series: | Rapid response report : summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Fondaparinux may offer both advantages and disadvantages when compared to older anticoagulants, such as enoxaparin. It is therefore important, in clinical practice, to assess the risk-benefit profile when determining which anticoagulant agent should be prescribed to patients. This should include considerations on both the clinical and economic evidence. The purpose of this review is therefore to compare the available evidence on fondaparinux to enoxaparin on patient with ACS in terms of their clinical effectiveness, safety, and cost-effectiveness |
|---|---|
| Item Description: | Title from PDF caption title |
| Physical Description: | 1 PDF file (36 pages) illustrations |